Neurotrophic factors represent a pivotal class of proteins indispensable for the intricate orchestration of neuron development, survival, and functionality within the nervous system. These multifaceted molecules wield significant influence by fostering neuronal growth, orchestrating differentiation, and regulating synaptic connectivity, thereby ensuring the resilience of neurons throughout various developmental stages and into adulthood. Among the foremost neurotrophic factors stands nerve growth factor (NGF), celebrated as the inaugural discovery in this domain, pivotal for the growth and sustenance of sensory neurons and indispensable in shaping the peripheral nervous system's architecture. Alongside NGF, brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5) emerge as stalwarts, each contributing uniquely to neuronal development, plasticity, and survival across both central and peripheral nervous systems. Perturbations in neurotrophic factor signaling pathways have been implicated in the pathogenesis of a spectrum of neurological disorders encompassing Alzheimer's disease, Parkinson's disease, and depression, underscoring their significance as potential therapeutic targets. Furthermore, these factors exhibit promise in promoting neuronal regeneration and repair post-neurotrauma or in the throes of neurodegenerative diseases, envisaging a realm where they might enhance neuronal survival, foster axonal growth, and bolster synaptic plasticity to ameliorate functional outcomes.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States